856 related articles for article (PubMed ID: 9018028)
1. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Block G; Liss C; Reines S; Irr J; Nibbelink D
Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
[TBL] [Abstract][Full Text] [Related]
2. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.
Koller WC; Hutton JT; Tolosa E; Capilldeo R
Neurology; 1999 Sep; 53(5):1012-9. PubMed ID: 10496260
[TBL] [Abstract][Full Text] [Related]
3. Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
Capildeo R
Neurology; 1998 Jun; 50(6 Suppl 6):S15-7; discussion S44-8. PubMed ID: 9633681
[TBL] [Abstract][Full Text] [Related]
4. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Bush DF; Liss CL; Morton A
Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
[TBL] [Abstract][Full Text] [Related]
5. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne UK; Rinne JO
Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Clin Neurol Neurosurg; 1992; 94(3):205-11. PubMed ID: 1327609
[TBL] [Abstract][Full Text] [Related]
7. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA
Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
[TBL] [Abstract][Full Text] [Related]
8. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Goetz CG; Tanner CM; Gilley DW; Klawans HL
Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
[TBL] [Abstract][Full Text] [Related]
10. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Rondot P; Ziegler M; Aymard N; Teinturier A
Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
[TBL] [Abstract][Full Text] [Related]
11. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
[TBL] [Abstract][Full Text] [Related]
14. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
15. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
16. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Dhall R; Kreitzman DL
Neurology; 2016 Apr; 86(14 Suppl 1):S13-24. PubMed ID: 27044646
[TBL] [Abstract][Full Text] [Related]
17. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
18. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
[No Abstract] [Full Text] [Related]
19. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
Hutton JT; Morris JL
Can J Neurol Sci; 1991 Nov; 18(4):467-71. PubMed ID: 1782612
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.
Grandas F; Martínez-Martín P; Linazasoro G
J Neurol; 1998 May; 245 Suppl 1():S31-3. PubMed ID: 9617721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
